decent solid guid rais pt
report decent result revenu ep ahead model
consensu solid outlook reflect strong companion anim
growth return growth livestock overal revenu growth well ahead
market updat model rais pt
continu view best-in-class anim health compani
stick hold rate stock base view rel
balanc risk/reward said see investor pay
themat appeal solid execut market leadership
report ep estim consensu
total revenu beat estim consensu
due strong ou growth vs estim particularli
companion anim vs revenu upsid off-set lower
gross margin vs model higher oper expens primarili
sg off-set lower tax drove upsid
takeaway quarter
view key takeaway expect growth anim
health market improv
continu grow revenu faster market outlook reflect
oper revenu growth manag remain confid
secur us approv simparica trio anticip launch
week later believ impact china african swine fever
asf level anticip flat low single-digit growth
china busi compani expect livestock sale across
speci return growth
increas revenu revenu
base primarili higher ou sale livestock
companion anim lower gross margin reflect
impact fx recent acquisit bump sg assumpt
base compani spend plan new ep
ep rais pt
assum stock trade ebitda
repres modest discount current multipl ebitda
tr target
page
expens attribut non-control zoeti inc
page
expens attribut non-control zoeti inc
page
manufacturing/human changeu manufacturing/human oper revenueu manufacturing/human profitexist apoquel gross marginexist apoquel gross zoeti inc
page
manufacturing/human changeu manufacturing/human oper revenueu manufacturing/human profitexist apoquel gross marginexist apoquel gross zoeti inc
zoeti largest anim health compani world sale compani strong
perform sinc spun nr consist above-market revenu
growth signific margin expans well-diversifi revenu base geograph
across companion food anim segment compani expand veterinari
diagnost market acquisit abaxi
despit hold rate stock view best-in-class anim health compani
attract combin sustain organ growth diversifi portfolio low-risk strategi
cash-pay model leverag infrastructur expect base busi drive solid revenu
earn growth next year may supplement select busi
develop new launch said believ attribut larg understood
marketplac would prefer attract entri point thu rate share hold
valuat risk
pt assum stock trade ebitda repres modest
discount current multipl ebitda downsid risk includ lower growth
livestock companion segment lower growth abaxi lower sale key product apoquel
cytopoint simparica consolid custom and/or competitor global econom downturn
advers fx trend upsid risk includ higher growth livestock companion abaxi
higher sale apoquel cytopoint simparica greater contribut new product
compani mention note
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
